- Home
- RCUS vs KBDC Comparison
RCUS vs KBDC Comparison
Compare RCUS & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- KBDC
- Stock Information
- Founded
- RCUS 2015
- KBDC 2021
- Country
- RCUS United States
- KBDC United States
- Employees
- RCUS N/A
- KBDC N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- KBDC
- Sector
- RCUS Health Care
- KBDC
- Exchange
- RCUS Nasdaq
- KBDC Nasdaq
- Market Cap
- RCUS 1.2B
- KBDC 1.1B
- IPO Year
- RCUS 2018
- KBDC N/A
- Fundamental
- Price
- RCUS $12.20
- KBDC $15.19
- Analyst Decision
- RCUS Buy
- KBDC Buy
- Analyst Count
- RCUS 8
- KBDC 4
- Target Price
- RCUS $20.71
- KBDC $16.50
- AVG Volume (30 Days)
- RCUS 772.4K
- KBDC 149.1K
- Earning Date
- RCUS 11-05-2025
- KBDC 08-11-2025
- Dividend Yield
- RCUS N/A
- KBDC 12.52%
- EPS Growth
- RCUS N/A
- KBDC N/A
- EPS
- RCUS N/A
- KBDC N/A
- Revenue
- RCUS $262,000,000.00
- KBDC N/A
- Revenue This Year
- RCUS N/A
- KBDC $193.84
- Revenue Next Year
- RCUS N/A
- KBDC $7.11
- P/E Ratio
- RCUS N/A
- KBDC N/A
- Revenue Growth
- RCUS 6.07
- KBDC N/A
- 52 Week Low
- RCUS $6.50
- KBDC $13.93
- 52 Week High
- RCUS $18.98
- KBDC $17.99
- Technical
- Relative Strength Index (RSI)
- RCUS 75.43
- KBDC 47.66
- Support Level
- RCUS $10.40
- KBDC $15.00
- Resistance Level
- RCUS $11.84
- KBDC $15.22
- Average True Range (ATR)
- RCUS 0.54
- KBDC 0.19
- MACD
- RCUS 0.16
- KBDC 0.04
- Stochastic Oscillator
- RCUS 98.35
- KBDC 65.45
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About KBDC Kayne Anderson BDC Inc. Common Stock
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.